OTC · KDEVF
Karolinska Development AB (publ)
$0.26$0.00 (0.0%)
Karolinska Development AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 58.0% below the high.
Loading market information…
OTC · MVRBF · USD
Stock price, earnings
Quote as of Feb 1, 2023, 02:30 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Medivir AB (publ)’s quoted price sits in the upper half of its reported 52-week range, 8.89% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Medivir AB (publ)’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Medivir AB (publ), established in 1987 and headquartered in Huddinge, Sweden, is a pharmaceutical company dedicated to the discovery, development, and commercialization of medicines, with a primary emphasis on oncology. The company's operations span both Sweden and international markets. Currently, Medivir markets Zoviduo (formerly Xerclear) for the treatment of labial herpes. Its pipeline of developmental compounds includes Remetinostat, an investigational therapy for MF cutaneous T-cell lymphoma and basal cell carcinoma. Additionally, the company is advancing MIV-818 for liver cancer, MIV-711 for osteoarthritis, and both Birinapant and IGM-8444, which are being developed to address solid tumors. Medivir also actively participates in collaborative ventures, such as a research partnership with the Drug Discovery and Development Platform at SciLifeLab focused on identifying antivirals for SARS CoV-2. Furthermore, it maintains licensing agreements with Tango Therapeutics for a preclinical research initiative and with Ubiquigent Limited for a preclinical program targeting USP7.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 05:00 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Apr 28, 2021 |
| -$0.18+67.27% vs estimate |
| $1.13M |
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$0.26$0.00 (0.0%)
Karolinska Development AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 58.0% below the high.
SEK 1.67-SEK 0.04 (-2.22%)
Oncopeptides AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 72.75% below the high.
$4.03+$0.03 (+0.75%)
Biostage, Inc.’s quoted price sits in the lower half of its reported 52-week range, 55.22% below the high.
$0.54-$0.00 (-0.37%)
Mindset Pharma Inc.’s quoted price sits in the upper half of its reported 52-week range, 3.74% below the high.
$0.03$0.00 (0.0%)
Abliva AB (publ)’s quoted price sits in the upper half of its reported 52-week range, 25.13% below the high.
$4.08$0.00 (0.0%)
Relief Therapeutics Holding AG’s quoted price sits in the lower half of its reported 52-week range, 73.06% below the high.
$0.11-$0.01 (-9.69%)
Small Pharma Inc.’s quoted price sits in the lower half of its reported 52-week range, 41.36% below the high.
$5.73$0.00 (0.0%)
Alpha Cognition Inc.: Healthcare · Biotechnology.
